From PolitiFact · Grace Abels · · 1m 30s
FDA Adds GLP-1 Blindness Warning
FDA requires new warnings for GLP-1 drugs after rare vision loss risk found.
In brief
FDA requires new warnings for GLP-1 drugs after rare vision loss risk found. FDA mandates updated warnings for GLP-1 medications due to higher risk of partial blindness from optic nerve condition. Originally reported by PolitiFact.
FDA new warning
The Food and Drug Administration will require updated warnings for GLP-1 medications about a rare optic nerve condition that can cause partial vision loss.
Risk found in study
Independent research and the FDA’s own review found patients taking GLP-1s may have a higher risk for the condition than people who don’t.
Study results
Among 134,200 patients in the FDA’s clinical trial analysis, 15 cases were detected: 10 among GLP-1 users and five among placebo users.
Condition explained
Nonarteritic anterior ischemic optic neuropathy causes painless sudden vision loss in part of the field of view and affects one eye initially.
Research triggered FDA action
A 2024 study found 17 out of 169 diabetic patients on semaglutide developed the vision loss condition versus four times the rate in non-users.
FDA meta-analysis
The FDA reviewed 126 clinical trials involving 134,253 patients and found 10 probable cases of vision loss in GLP-1 users versus five in placebo groups.
Expert opinion
Dr. Scott Kahan says the risk is real but rare and that the new warning won’t change prescribing but may improve patient conversations.
Patient advice
Patients should discuss preexisting eye conditions with doctors and not stop GLP-1s without medical guidance.
The essence
FDA mandates updated warnings for GLP-1 medications due to higher risk of partial blindness from optic nerve condition.